Assembly Biosciences Inc. Common Stock (ASMB)
Stock · NASDAQ · Health Care
$20.12as of 10/16/2026
Price chart
Active signals
ASMB Signal Track Record
How signals performed across all stocks →What ASMB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 42 | -3.8% | 43% | September 18, 2026 |
| Bollinger Band Breakout | 23 | +1.5% | 57% | August 13, 2026 |
| Bollinger Band Breakdown | 20 | +2.6% | 55% | September 14, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -1.8% | 40% | September 14, 2026 |
| Any 20-session window (baseline) | 0.0% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ASMB
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 73
- Website
- www.assemblybio.com/
Fundamentals
- 1-day range
- $19.96$20.63
- Market cap
- $420.36M
- P/E (trailing)
- 333.50
- P/E (forward)
- -7.81
- EPS (trailing)
- $-0.16
- Dividend yield
- —
- Beta
- 1.21
- Avg. volume
- 284.6K
How Assembly Biosciences Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Assembly Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ASMBAssembly Biosciences Inc. Common Stock$20.09▼ 2.33%Market cap $420.36MP/E 333.50$19.98$39.71
- PBYIPuma Biotechnology Inc Common Stock$9.83▼ 6.56%Market cap $413.30MP/E 20.62$4.58$10.5
- KMDAKamada Ltd. Ordinary Shares$7.76▼ 0.89%Market cap $411.88MP/E 20.30$6.55$9.35
- LRMRLarimar Therapeutics Inc. Common Stock$1.99▼ 0.25%Market cap $436.31MP/E —$2.06$6.42
- AVIRAtea Pharmaceuticals Inc. Common Stock$4.32▼ 4.64%Market cap $399.34MP/E —$2.87$6.45
- ABEOAbeona Therapeutics Inc. Common Stock$4.43▼ 4.73%Market cap $393.27MP/E 5.50$4$7.65
- PRTAProthena Corporation plc Ordinary Shares$8.35▼ 1.76%Market cap $449.19MP/E —$7.73$11.8
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ASMB Assembly Biosciences Inc. Common Stock | $420.36M | 333.50 | $20.09 | ▼ 2.33% | $19.98$39.71 |
| PBYI Puma Biotechnology Inc Common Stock | $413.30M | 20.62 | $9.83 | ▼ 6.56% | $4.58$10.5 |
| KMDA Kamada Ltd. Ordinary Shares | $411.88M | 20.30 | $7.76 | ▼ 0.89% | $6.55$9.35 |
| LRMR Larimar Therapeutics Inc. Common Stock | $436.31M | — | $1.99 | ▼ 0.25% | $2.06$6.42 |
| AVIR Atea Pharmaceuticals Inc. Common Stock | $399.34M | — | $4.32 | ▼ 4.64% | $2.87$6.45 |
| ABEO Abeona Therapeutics Inc. Common Stock | $393.27M | 5.50 | $4.43 | ▼ 4.73% | $4$7.65 |
| PRTA Prothena Corporation plc Ordinary Shares | $449.19M | — | $8.35 | ▼ 1.76% | $7.73$11.8 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026Yahoo · 10/5/2026
- Assembly Biosciences To Present New Phase 1a Data From Its ABI-6250 Program At The Liver Meeting 2026Benzinga · 10/5/2026
- Best Momentum Stocks to Buy for September 17thYahoo · 9/17/2026
- New Strong Buy Stocks for September 17thYahoo · 9/17/2026
Insider Activity
Insider Actions →- Jeanette M. Bjorkquist · June 17, 2026 · Sale29 @ $23.25
- John G. McHutchison · June 4, 2026 · Grant8.0K
- Susan Mahony · June 4, 2026 · Grant8.0K
- Johnson-Pratt Lisa · June 4, 2026 · Grant8.0K
- Michael Houghton · June 4, 2026 · Grant8.0K
- Consylman Gina · June 4, 2026 · Grant8.0K
- ALTIG ANTHONY E · June 4, 2026 · Grant8.0K
- GILEAD SCIENCES, INC. · May 26, 2026 · Grant471.7K @ $26.5
Institutional Ownership
March 31, 2026
- Total shares held
- 13.42M
- Total value held
- $371.09M
- Institutional holders
- 71
- Unknown4.51M
- Unknown1.23M
- Unknown1.02M
- Unknown1.00M
- Unknown849.3K
- Unknown665.3K
- Unknown490.4K
- Unknown411.2K
- Unknown344.1K
- Unknown296.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Assembly Biosciences to Present Phase 1a ABI-6250 Data at AASLD 2026
Assembly Biosciences announced that it will share Phase 1a safety, tolerability and target engagement results for its liver‑focused candidate ABI‑6250 at the AASLD Liver Meeting 2026. The data will be the first clinical readout for the program and could provide insight into the drug’s early performance. The announcement comes as the stock trades near its recent support level.
Assembly Biosciences to Present Phase 1a ABI-6250 Data at AASLD 2026. Assembly Biosciences announced that it will share Phase 1a safety, tolerability and target engagement results for its liver‑focused candidate ABI‑6250 at the AASLD Liver Meeting 2026. The data will be the first clinical readout for the program and could provide insight into the drug’s early performance. The announcement comes as the stock trades near its recent support level.